Friday, October 10, 2025

Stocks To Buy: Jefferies sees 40% upside for this defence stock despite Q1 results miss

Date:

Shares of Data Patterns (India) Ltd. gained 6.5% on Monday, August 11, as brokerage firm Jefferies projected a 40% upside on the stock post its first quarter earnings.Jefferies has a “buy” rating on the stock with a price target of ₹3,400 per share.

It said Data Patterns’ first quarter sales were a big miss compared to their expectations, which the management highlighted was primarily due to revenue deferment of ₹270 crore, which is expected to come in during the second quarter.

Despite the deferment in revenue, the growth guidance for financial year 2026 was maintained at 20% to 25%, by the company.
The first quarter order flow is up 4.8 times from the previous year at ₹180 crore and orders worth ₹320 crore have been received so far in financial year 2026.Jefferies believes that in-house technology in a growing defence should reflect in the topline and bottomline tripling between financial year 2026-2030.

Of the 12 analysts that have coverage on the stock, 10 have a “buy” rating and one each have “hold” and “sell” ratings.

Shares of Data Patterns increased 6.5% to hit an intraday high of ₹2,585.7 apiece on Monday. The stock was up 3.8% at ₹2,520.2 apiece at 1.40 pm. The stock has declined 11.9% in the past month.

Also Read: PG Electroplast shares fall 17% after equity worth ₹526 crore changes hands

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

US to host Qatar F-15 training facility at Mountain Home Air Force base in Idaho

US Defence Secretary Pete Hegseth on Friday (October 10)...

Blast at Tennessee explosives plant leaves multiple people dead, missing: sheriff

An explosion at a Tennessee military munitions plant left...

The ultimate guide to credit repair: Fixing your financial past

आपके क्रेडिट की मरम्मत आम तौर पर एक लंबी...

Zydus Lifesciences gets nod from Health Canada for Liothyronine tablets

Zydus Lifesciences Ltd said on Monday it has received...